A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor performance status (≥2), has not been fully elucidated. We...

Full description

Bibliographic Details
Main Authors: Daichi Fujimoto, MD, Satoru Miura, MD, PhD, Kenichi Yoshimura, MD, PhD, Kazushige Wakuda, MD, Yuko Oya, MD, Koji Haratani, MD, PhD, Shoichi Itoh, MD, Takehiro Uemura, MD, PhD, Ryotaro Morinaga, MD, PhD, Takayuki Takahama, MD, PhD, Kazuhisa Nakashima, MD, Motoko Tachihara, MD, PhD, Go Saito, MD, Junko Tanizaki, MD, PhD, Kohei Otsubo, MD, PhD, Satoshi Ikeda, MD, Hirotaka Matsumoto, MD, Satoshi Hara, MD, Akito Hata, MD, Takeshi Masuda, MD, PhD, Nobuyuki Yamamoto, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:JTO Clinical and Research Reports
Subjects:
Immune checkpoint inhibitor
Pembrolizumab
Pneumonitis
Programmed Death-1
Programmed Death-Ligand 1
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321001247

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321001247

Similar Items